Table 1.
Patient characteristics
| Salvage subtypes |
Salvage total | Primary total | p value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Whole gland | Matched primary | p value | Focal gland | Matched primary | p value | Whole/focal p value | ||||
| Patients, n | 49 | 49 | – | 86 | 86 | – | – | 135 | 135 | – |
| Age (yr), median (IQR) | 70 (63, 73) | 68 (65, 74) | 0.765 | 70 (64, 72) | 69.5 (67, 73) | 0.118 | 0.509 | 70 (64, 73) | 69 (66, 73) | 0.158 |
| BMI, median (IQR) | 27.7 (26, 30) | 28 (27, 30) | 0.285 | 27.8 (26, 30) | 28 (26, 29) | 0.751 | 0.798 | 27.7 (25.9, 30.6) | 28 (26, 29) | 0.736 |
| ASA, n (%) | ||||||||||
| 1 | 1 (2.0) | 0 | 0.257 | 3 (3.5) | 4 (4.7) | 0.134 | 0.568 | 4 (3.0) | 4 (3.0) | 0.061 |
| 2 | 43 (87.8) | 48 (98.0) | 76 (88.4) | 80 (93.0) | 119 (88.1) | 128 (94.8) | ||||
| 3 | 5 (10.2) | 1 (2.0) | 7 (8.1) | 2 (2.3) | 12 (8.9) | 3 (2.2) | ||||
| CCI ≥1, n (%) | 8 (16.3) | 10 (20.4) | 0.804 | 17 (19.8) | 17 (19.8) | >0.999 | >0.999 | 25 (18.5) | 27 (20.0) | >0.999 |
| PSA preop, median (IQR) | 5.50 (3.65, 11.00) | 6.00 (4.40, 7.85) | 0.754 | 5.90 (3.58, 10.35) | 6.00 (5.00, 8.38) | 0.636 | 0.742 | 5.8 (3.6, 10.7) | 6 (4.9, 8.1) | 0.813 |
| T stage preop, n (%) | ||||||||||
| T1 | 1 (2.0) | 3 (6.1) | 0.746 | 2 (2.3) | 2 (2.3) | 0.346 | 0.089 | 3 (2.2) | 5 (3.7) | 0.614 |
| T2 | 21 (42.9) | 19 (38.8) | 50 (58.1) | 43 (50.0) | 71 (52.6) | 62 (45.9) | ||||
| T3 | 27 (55.1) | 27 (55.1) | 34 (39.5) | 41 (47.7) | 61 (45.2) | 68 (50.4) | ||||
| Gleason preop, n (%) | ||||||||||
| 3 + 3 | 2 (4.1) | 0 | 0.083 | 4 (4.7) | 0 | 0.063 | 0.002 | 6 (4.4) | 0 (0) | 0.613 |
| 3 + 4 | 12 (24.5) | 20 (40.8) | 42 (48.8) | 37 (43.0) | 54 (40.0) | 57 (42.2) | ||||
| 3 + 5 | 0 | 1 (2.0) | 1 (1.2) | 0 | 1 (0.7) | 1 (0.7) | ||||
| 4 + 3 | 16 (32.7) | 18 (36.7) | 23 (26.7) | 24 (27.9) | 39 (28.9) | 42 (31.1) | ||||
| 4 + 4 | 8 (16.3) | 4 (8.2) | 8 (9.3) | 15 (17.4) | 16 (11.9) | 19 (14.1) | ||||
| 4 + 5 | 9 (18.4) | 5 (10.2) | 8 (9.3) | 8 (9.3) | 17 (12.6) | 13 (9.6) | ||||
| 5 + 4 | 2 (4.1) | 1 (2.0) | 0 | 2 (2.3) | 2 (1.5) | 3 (2.2) | ||||
| EAU risk, n (%) | ) | |||||||||
| Low | 0 | 0 | >0.999 | 0 | 0 | 0.223 | 0.099 | 0 | 0 | 0.307 |
| Intermediate | 8 (16.3) | 8 (16.3) | 25 (29.1) | 18 (20.9) | 33 (24.4) | 26 (19.3) | ||||
| High | 41 (83.7) | 41 (83.7) | 61 (70.9) | 68 (79.1) | 102 (75.6) | 109 (80.7) | ||||
ASA = American Society of Anaesthesiologists score; BMI = body mass index; CCI = Charlson comorbidity index (non–age adjusted); EAU = European Association of Urology; IQR = interquartile range; n = numbers; PSA = prostate-specific antigen.